Home/Hedge Fund Intelligence/Zenas BioPharma, Inc.
Nasdaq: ZBIOStockForm 13F30 Jun 2026

Hedge funds that hold Zenas BioPharma, Inc. Nasdaq: ZBIO

CUSIP 98937L105 · who reports it, how much, and how much it matters to them

26 of the 720 hedge fund managers we track reported shares of Zenas BioPharma, Inc. (Nasdaq: ZBIO) on Form 13F for 30 June 2026. Between them they reported USD 267m. The largest position belongs to Polar Capital LLP, at USD 61m. The manager with the most riding on it is Fairmount Funds Management, where it is 4.0% of the reported book.

Managers reporting it26of 720 we track
Value they reportUSD 267mshares only, 30 Jun 2026
Funds they run346with a file on PPLI.com
Largest positionUSD 61mPolar Capital LLP
Typical weight0.0%median share of a manager's book
Heaviest weight4.0%Fairmount Funds Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

26 managers, USD 267m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Zenas BioPharma, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Polar Capital LLP26 funds on PPLI.comUSD 61m0.1%
2Fairmount Funds Management2 funds on PPLI.comUSD 60m4.0%
3Two Sigma Investments35 funds on PPLI.comUSD 21m0.0%
4ECOR1 Capital3 funds on PPLI.comUSD 20m1.0%
5Millennium Management6 funds on PPLI.comUSD 17m0.0%
6Balyasny Asset Management25 funds on PPLI.comUSD 15m0.0%
7Arrowmark Colorado Holdings24 funds on PPLI.comUSD 15m0.6%
8Rock Springs Capital Management2 funds on PPLI.comUSD 13m0.6%
9Marshall Wace LLP84 funds on PPLI.comUSD 8.2m0.0%
10Sphera Funds Management1 fund on PPLI.comUSD 5.9m0.8%
11Walleye Capital8 funds on PPLI.comUSD 5.3m0.0%
12Sio Capital Management4 funds on PPLI.comUSD 5.3m0.9%
13Citadel Advisors32 funds on PPLI.comUSD 5m0.0%
14Voleon Capital Management13 funds on PPLI.comUSD 4.2m0.1%
15Squarepoint Ops7 funds on PPLI.comUSD 3.2m0.0%
16Verition Fund Management3 funds on PPLI.comUSD 1.9m0.0%
17J. Goldman & Co.1 fund on PPLI.comUSD 1.7m0.0%
18Exome Asset Management2 funds on PPLI.comUSD 1.3m0.8%
19Burkehill Global Management5 funds on PPLI.comUSD 1m0.0%
20Atom Investors1 fund on PPLI.comUSD 943,0000.1%
21Boothbay Fund Management2 funds on PPLI.comUSD 845,0000.0%
22POINT72 Asset Management17 funds on PPLI.comUSD 410,0000.0%
23Brevan Howard Capital Management39 funds on PPLI.comUSD 372,0000.0%
24Engineers Gate Manager1 fund on PPLI.comUSD 329,0000.0%
25Scientech Research2 funds on PPLI.comUSD 229,0000.2%
26Freestone Grove Partners1 fund on PPLI.comUSD 250.0%
Next: where it matters most
Where it matters most

For Fairmount Funds Management it is 4.0% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Fairmount Funds ManagementUSD 60m4.0%
2ECOR1 CapitalUSD 20m1.0%
3Sio Capital ManagementUSD 5.3m0.9%
4Exome Asset ManagementUSD 1.3m0.8%
5Sphera Funds ManagementUSD 5.9m0.8%
6Rock Springs Capital ManagementUSD 13m0.6%
7Arrowmark Colorado HoldingsUSD 15m0.6%
8Scientech ResearchUSD 229,0000.2%
9Polar Capital LLPUSD 61m0.1%
10Atom InvestorsUSD 943,0000.1%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Zenas BioPharma, Inc.

What is the ticker symbol of Zenas BioPharma, Inc.?

Zenas BioPharma, Inc. trades under the symbol ZBIO on the Nasdaq. Its CUSIP, the code used on Form 13F, is 98937L105.

Which hedge funds own Zenas BioPharma, Inc. (Nasdaq: ZBIO)?

26 of the 720 hedge fund managers PPLI.com tracks reported Zenas BioPharma, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Polar Capital LLP (USD 61m), Fairmount Funds Management (USD 60m), Two Sigma Investments (USD 21m), ECOR1 Capital (USD 20m) and Millennium Management (USD 17m).

How many hedge funds hold Zenas BioPharma, Inc.?

26 managers in our coverage reported it, and between them they run 346 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Zenas BioPharma, Inc.?

Fairmount Funds Management, where the position was 4.0% of the reported 13F book at 30 June 2026.

Does this show who is short Zenas BioPharma, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Zenas BioPharma, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.